Certified Principal Investigator (CPI®) — Questions and Answers

Question 1: What is the difference between 'efficacy' and 'effectiveness' in clinical research?

Efficacy is measured under controlled trial conditions; effectiveness reflects real-world performance (Correct answer)
Efficacy measures real-world performance; effectiveness measures trial performance
Efficacy applies only to devices; effectiveness applies to drugs
They are interchangeable terms in regulatory submissions

Correct answer: Efficacy is measured under controlled trial conditions; effectiveness reflects real-world performance

Efficacy refers to how well a treatment works under ideal, controlled conditions, while effectiveness reflects performance in routine clinical practice.

Question 2: What is a work breakdown structure in CPI practice?

Hierarchical decomposition of deliverables into manageable work packages (Correct answer)
Employee schedule report
Organizational reporting diagram
Team member roster

Correct answer: Hierarchical decomposition of deliverables into manageable work packages

A WBS breaks total scope into progressively smaller components for easier estimation, scheduling, and tracking.

Question 3: What is the primary purpose of a Data Safety Monitoring Board (DSMB) in a clinical trial?

To monitor accumulating data and protect participant safety, recommending early stopping if needed (Correct answer)
To market the investigational product to physicians
To ensure all enrolled participants complete follow-up visits
To audit the sponsor's financial accounts

Correct answer: To monitor accumulating data and protect participant safety, recommending early stopping if needed

A DSMB conducts interim analyses of unblinded data to identify safety signals or clear efficacy, with authority to recommend stopping or modifying a trial.

Question 4: In Bayesian statistics applied to clinical trials, what does the 'prior distribution' represent?

The distribution of placebo outcomes in the trial
Pre-existing knowledge or belief about a parameter before observing trial data (Correct answer)
The distribution of p-values across multiple studies
The posterior probability of the primary endpoint being met

Correct answer: Pre-existing knowledge or belief about a parameter before observing trial data

The prior distribution in Bayesian analysis encodes existing information or beliefs about a parameter, which is then updated with observed trial data to form the posterior.

Question 5: Standard Precautions in a clinical research setting apply to:

Immunocompromised participants exclusively
All blood and body fluids regardless of diagnosis (Correct answer)
Participants on Contact Precautions only
Only participants known to have communicable diseases

Correct answer: All blood and body fluids regardless of diagnosis

Standard Precautions assume all blood and body fluids are potentially infectious and apply to every participant regardless of known infection status.

Question 6: Which of the following best describes the 'stopping rules' in a clinical trial protocol?

Guidelines for when the IRB can revoke site approval
FDA-mandated timelines for IND withdrawal
Predefined criteria that trigger immediate discontinuation of a participant or the entire trial (Correct answer)
Sponsor authority to end the trial for business reasons

Correct answer: Predefined criteria that trigger immediate discontinuation of a participant or the entire trial

Stopping rules are pre-specified safety thresholds in the protocol that mandate participant withdrawal or trial suspension when specific adverse events or data patterns occur.

Question 7: An investigator wants to add a co-investigator to the study team mid-trial. What is required before this person can perform study tasks?

The co-investigator may begin immediately if they hold an active medical license
The sponsor must formally amend Form FDA 1572 before any tasks can be delegated
The co-investigator must complete a 30-day observation period before performing independent study tasks
The co-investigator must be trained on the protocol, qualified for their delegated tasks, added to the delegation log, and the IRB notified per institutional requirements (Correct answer)

Correct answer: The co-investigator must be trained on the protocol, qualified for their delegated tasks, added to the delegation log, and the IRB notified per institutional requirements

New study team members must receive protocol training, be qualified for their assigned tasks, be documented on the delegation log, and meet IRB notification requirements before performing study duties.

Question 8: Which of the following BEST describes the purpose of an Institutional Review Board (IRB) continuing review in the context of patient safety?

To assess ongoing risks to participants in light of accumulated safety data and ensure protections remain adequate (Correct answer)
To renegotiate investigator contracts annually
To verify that the investigator has met enrollment targets
To audit financial disclosures from sponsors

Correct answer: To assess ongoing risks to participants in light of accumulated safety data and ensure protections remain adequate

Continuing review allows the IRB to evaluate evolving risk-benefit profiles based on new safety information and adjust participant protections accordingly.

Question 9: A CPI is reviewing a research proposal that offers $500 per visit to participants in a 10-visit study. Which ethical concern is MOST relevant?

The total payment exceeds the IRB's standard reimbursement cap
Excessive payment may constitute undue inducement, compromising voluntariness of consent (Correct answer)
FDA regulations prohibit monetary compensation in clinical trials
Monetary payment is only permissible for Phase III and IV trials

Correct answer: Excessive payment may constitute undue inducement, compromising voluntariness of consent

Undue inducement occurs when payment is so large that it compromises participants' ability to freely weigh risks and benefits, threatening the voluntariness of consent.

Question 10: When a protocol specifies 'washout period' requirements before study drug initiation, the primary purpose is to:

Allow subjects to recover psychologically from prior treatments
Eliminate prior treatment effects that could confound study results or cause interactions (Correct answer)
Ensure adequate time for informed consent documentation
Meet regulatory timelines for subject enrollment

Correct answer: Eliminate prior treatment effects that could confound study results or cause interactions

Washout periods eliminate residual effects of prior treatments to reduce confounding and prevent drug-drug interactions.

Question 11: An investigator receives new safety information from the sponsor about an increased risk associated with the investigational product. What is the MOST immediate obligation?

Assess the impact on enrolled subjects and notify the IRB in a timely manner (Correct answer)
Wait for a protocol amendment before taking any action
Disregard unless FDA issues a formal safety alert
Suspend enrollment until the IRB reviews the information

Correct answer: Assess the impact on enrolled subjects and notify the IRB in a timely manner

Investigators must promptly assess new safety information and report it to the IRB, as it may require consent form updates or protocol changes to protect subjects.

Question 12: According to GCP guidelines, how should source documents be corrected if an error is found?

Draw a single line through the error, write the correction, initial, and date the change (Correct answer)
Use correction fluid (white-out) to cover the error and write the correct information above it
Delete the incorrect entry entirely and re-enter the correct information on the same line
Scan the original document and retype the correct information in a separate electronic file

Correct answer: Draw a single line through the error, write the correction, initial, and date the change

GCP requires corrections to source documents to allow the original entry to remain legible; the corrector must draw a single line through the error, write the correction, and initial and date the change.

Question 13: What is the importance of continuing education for CPI professionals in Pharmacology & Medication Management?

Filling time between engagements
Only for new professionals
Justifying higher fees
Maintaining current knowledge and adapting to industry changes (Correct answer)

Correct answer: Maintaining current knowledge and adapting to industry changes

Continuing education keeps professionals current with developments and best practices while meeting certification requirements.

Question 14: A blinded Phase III trial uses placebo control. The study drug is a capsule with a distinctive bitter taste. Participants frequently guess their assignment. This is an example of which methodological problem?

Unblinding due to pharmacological clues (Correct answer)
Attrition bias from dropouts
Selection bias in randomization
Detection bias in outcome ascertainment

Correct answer: Unblinding due to pharmacological clues

Distinctive organoleptic properties such as taste or smell can unblind participants, compromising the integrity of blinding and introducing performance and reporting bias.

Question 15: In a clinical trial protocol, an 'allowed concomitant medication' list is provided. A subject requires a drug NOT on the list. The investigator should:

Automatically discontinue the subject from the trial
Consult the protocol's prohibited medication section, contact the sponsor, and document the decision (Correct answer)
Withhold the medication until the subject completes the trial
Prescribe the medication and document it as standard of care

Correct answer: Consult the protocol's prohibited medication section, contact the sponsor, and document the decision

When a concomitant medication is not addressed, the investigator must cross-reference prohibited lists, consult the sponsor, and carefully document the clinical rationale.

Question 16: Why is regular review important in CPI risk management?

Conditions change and new risks emerge requiring updates (Correct answer)
Only needed after incidents
Prohibited more than annually
Assessments stay valid forever

Correct answer: Conditions change and new risks emerge requiring updates

Regular reviews ensure assessments remain current as conditions change and lessons from incidents are incorporated.

Question 17: Which of the following qualifies as a criterion for classifying an adverse event as 'serious'?

Persistent or significant disability or incapacity (Correct answer)
Any adverse event requiring a dose reduction
Grade 2 fatigue lasting more than one week
Nausea requiring antiemetic therapy

Correct answer: Persistent or significant disability or incapacity

Persistent or significant disability or incapacity is one of the six FDA-defined criteria that classify an adverse event as serious.

Question 18: Emergency research conducted under 21 CFR 50.24 (exception from informed consent) requires which prospective community consultation step?

Public disclosure and community consultation before initiating the research (Correct answer)
Signed consent from community representatives
Written agreement from local hospital administrators
IRB waiver of the community consultation requirement

Correct answer: Public disclosure and community consultation before initiating the research

21 CFR 50.24 mandates prospective community consultation and public disclosure as prerequisites before conducting exception from informed consent research.

Question 19: Which of the following BEST describes the concept of 'therapeutic misconception' in clinical research ethics?

An investigator's erroneous assumption that all research participants are cognitively capable of consent
The incorrect belief that placebos are always inert and cannot cause harm
The mistaken view that IRB approval guarantees that a study is safe for all participants
A participant's false belief that research procedures are designed primarily for their individual therapeutic benefit rather than to generate generalizable knowledge (Correct answer)

Correct answer: A participant's false belief that research procedures are designed primarily for their individual therapeutic benefit rather than to generate generalizable knowledge

Therapeutic misconception occurs when participants conflate clinical research with clinical care and believe research interventions are personalized to their medical benefit.

Question 20: An investigator is also a treating physician for a potential study participant. Which conflict of interest concern is MOST relevant to informed consent?

The dual role may impair the participant's ability to freely decline or withdraw without fearing impact on their clinical care (Correct answer)
The investigator may underestimate the participant's medical literacy
The IRB will automatically disqualify the investigator from obtaining consent
The investigator may disclose proprietary sponsor information during the consent process

Correct answer: The dual role may impair the participant's ability to freely decline or withdraw without fearing impact on their clinical care

The therapeutic misconception and fear of jeopardizing ongoing care can compromise voluntariness when the treating physician is also the investigator.

Question 21: When must an investigator obtain a new or revised informed consent from an already-enrolled participant?

Only if the participant specifically requests an updated consent form
When the IRB approves a protocol amendment that contains information that might affect a participant's willingness to continue (Correct answer)
Whenever the sponsor issues a new investigator brochure
At each annual study visit as a standard re-confirmation of original consent

Correct answer: When the IRB approves a protocol amendment that contains information that might affect a participant's willingness to continue

Re-consent is required when new information emerges (such as new risks) that might affect participants' decisions about continued participation in the trial.

Question 22: What is the purpose of maintaining a subject screening and enrollment log?

To list all adverse events reported during the trial
To track site staff training completion
To document all subjects screened, reasons for screen failures, and enrolled subject identifiers (Correct answer)
To record sponsor monitoring visit dates

Correct answer: To document all subjects screened, reasons for screen failures, and enrolled subject identifiers

Screening and enrollment logs document all subjects considered for the trial, screen failure reasons, and enrolled subject IDs to demonstrate recruitment transparency.

Question 23: Which of the following must be documented each time an investigational product is dispensed to a study subject?

Sponsor's manufacturing facility address and batch certificate
Subject's social security number and emergency contact
Subject's insurance information and copay amount
Date, quantity dispensed, lot number, expiration date, and subject identifier (Correct answer)

Correct answer: Date, quantity dispensed, lot number, expiration date, and subject identifier

Dispensing records must capture date, quantity, lot number, expiration date, and subject identifier to create a complete chain of custody and enable reconciliation.

Question 24: A physician investigator notices that laboratory values collected at one site are consistently 10% higher than other sites. This is an example of:

Random error
Systematic bias (Correct answer)
Type II error
Sampling variability

Correct answer: Systematic bias

Consistent directional differences across a site indicate systematic bias, often due to equipment calibration or procedural differences.

Question 25: What is document version control in CPI?

Printing every draft
No change tracking
Tracking changes, identifying current versions, and maintaining history (Correct answer)
Same names for all files

Correct answer: Tracking changes, identifying current versions, and maintaining history

Version control tracks revisions, identifies current versions, and maintains change history to ensure document integrity.

Question 26: Why is regular review important in CPI risk management?

Conditions change and new risks emerge requiring updates (Correct answer)
Assessments stay valid forever
Only needed after incidents
Prohibited more than annually

Correct answer: Conditions change and new risks emerge requiring updates

Regular reviews ensure assessments remain current as conditions change and lessons from incidents are incorporated.

Question 27: When evaluating inclusion/exclusion criteria, a physician investigator discovers a subject meets all inclusion criteria but has one exclusion criterion that appears borderline. What is the appropriate next step?

Contact the sponsor or medical monitor for clarification before enrolling (Correct answer)
Have the subject sign the consent form and decide eligibility after enrollment
Enroll the subject and document the deviation
Exclude the subject without further inquiry

Correct answer: Contact the sponsor or medical monitor for clarification before enrolling

Borderline eligibility situations require consultation with the sponsor or medical monitor before enrollment to protect subject safety and protocol integrity.

Question 28: Which FDA system is used to track post-market adverse event reports for drugs and medical devices?

IND Safety Reporting Database
FAERS (FDA Adverse Event Reporting System) (Correct answer)
PRISM (Post-market Risk Identification)
CTMS (Clinical Trial Management System)

Correct answer: FAERS (FDA Adverse Event Reporting System)

FAERS (FDA Adverse Event Reporting System) is the FDA's post-market pharmacovigilance database used to store and analyze adverse event and medication error reports.

Question 29: Which scenario would most clearly require convening a full IRB board review rather than expedited review?

A survey study involving adults about dietary habits
A Phase III trial of an investigational cancer chemotherapy (Correct answer)
Collection of hair clippings for genetic analysis with no identifiers
A minimal-risk chart review study

Correct answer: A Phase III trial of an investigational cancer chemotherapy

Phase III chemotherapy trials involve more than minimal risk and must receive full board review by the IRB.

Question 30: Which of the following is considered a source document in a clinical trial?

The original hospital medical record containing lab results (Correct answer)
The protocol synopsis distributed to IRB members
The sponsor's monitoring visit report
The completed CRF submitted to the sponsor

Correct answer: The original hospital medical record containing lab results

Source documents are original records from which CRF data are transcribed, including hospital charts, lab reports, and clinic notes.

Question 31: Why is it important for investigators to report adverse events?

To monitor study progress
To ensure patient safety and make necessary adjustments (Correct answer)
To increase participant numbers
To reduce study costs

Correct answer: To ensure patient safety and make necessary adjustments

Reporting adverse events is critical for monitoring the safety profile of an investigational treatment or intervention. Prompt reporting allows investigators and regulatory bodies to assess potential risks, identify patterns, and make timely decisions, such as modifying the protocol or stopping the study, to protect participant safety.

Question 32: Which infection surveillance metric is MOST useful for benchmarking infection rates across multiple clinical trial sites?

Total number of infections per site
Percentage of participants who received antibiotics
Number of positive cultures per site per month
Infection rate per 1,000 participant-days (Correct answer)

Correct answer: Infection rate per 1,000 participant-days

Infection rate per 1,000 participant-days accounts for varying enrollment sizes and follow-up durations, enabling valid cross-site comparisons.

Question 33: When a protocol specifies 'individualized dose titration,' what principle distinguishes this from fixed-dose protocols?

Dose selection is based solely on the subject's body weight
The investigator freely prescribes any dose without protocol constraints
Doses are adjusted based on individual subject response, tolerability, or biomarker levels within protocol-defined limits (Correct answer)
All subjects receive identical doses to ensure comparability of data

Correct answer: Doses are adjusted based on individual subject response, tolerability, or biomarker levels within protocol-defined limits

Individualized dose titration adjusts doses for each subject based on defined criteria such as response or toxicity, within protocol-specified minimum and maximum limits.

Question 34: What are principles of good documentation in CPI?

Only document positives
Include personal opinions
Speed is the only factor
Accuracy, completeness, timeliness, objectivity, and legibility (Correct answer)

Correct answer: Accuracy, completeness, timeliness, objectivity, and legibility

Good documentation must be accurate, complete, timely, objective, and legible.

Question 35: According to FDA regulations, who at the investigational site bears primary responsibility for investigational product accountability?

The IRB pharmacist representative
The principal investigator (Correct answer)
The study coordinator
The sponsor's clinical research associate

Correct answer: The principal investigator

Under 21 CFR Part 312, the principal investigator is ultimately responsible for ensuring investigational product is used only for subjects under their supervision and that accountability records are maintained.

Question 36: What determines the 'expectedness' of an adverse reaction in an IND study?

Whether the IRB anticipated the reaction during protocol review
The subject's pre-existing medical history and comorbidities
Whether the reaction is described in the current Investigator's Brochure (IB) or reference safety information (Correct answer)
The frequency at which the reaction has occurred in the study population

Correct answer: Whether the reaction is described in the current Investigator's Brochure (IB) or reference safety information

Expectedness is based on whether the adverse reaction is listed in the current Investigator's Brochure or reference safety information for the investigational product.

Question 37: In clinical research, which of the following BEST describes the 'blame-free' culture essential to patient safety?

Staff are never held accountable for errors regardless of intent
Errors are reported without fear of punishment so systemic problems can be identified and fixed (Correct answer)
Only supervisors review error reports to prevent staff anxiety
Near-misses are excluded from reporting to reduce administrative burden

Correct answer: Errors are reported without fear of punishment so systemic problems can be identified and fixed

A blame-free culture encourages transparent reporting by ensuring that individuals can report errors without fear of punitive consequences, enabling system improvement.

Question 38: An investigator conducting a multi-site trial identifies that another site is not following GCP. What is their responsibility?

No responsibility exists, as each investigator is only accountable for their own site
Report the non-compliance directly to the FDA on behalf of the other site
Report concerns to the sponsor so the sponsor can address the issue with the non-compliant site (Correct answer)
Request the IRB to revoke approval from the non-compliant site

Correct answer: Report concerns to the sponsor so the sponsor can address the issue with the non-compliant site

An investigator's primary responsibility is to their own site; concerns about other sites should be escalated to the sponsor, who bears oversight responsibility across all sites.

Question 39: What is a needs assessment in CPI Infection Control & Prevention practice?

Office supply list
Property appraisal
Benefits survey
Identifying gaps between current conditions and desired outcomes (Correct answer)

Correct answer: Identifying gaps between current conditions and desired outcomes

A needs assessment identifies gaps between current performance and desired outcomes to justify improvements.

Question 40: What is a statistical test used for in clinical research?

To recruit participants
To improve patient outcomes
To assess if findings are significant and generalizable (Correct answer)
To monitor patient symptoms

Correct answer: To assess if findings are significant and generalizable

Statistical tests are applied in clinical research to analyze collected data and determine the probability that observed results occurred by chance. They help researchers assess the statistical significance of their findings, allowing them to draw valid conclusions about the effectiveness of interventions and their generalizability to the target population.

Question 41: What is a clinical research protocol?

A list of recruited participants
The final report
A written summary of the research findings
A plan that outlines the study's objectives and procedures (Correct answer)

Correct answer: A plan that outlines the study's objectives and procedures

A clinical research protocol is a detailed document that serves as the blueprint for a clinical study. It meticulously describes the study's rationale, objectives, design, methodology, statistical considerations, and organizational aspects, ensuring consistency, safety, and scientific integrity throughout the research.

Question 42: What should investigators do when they encounter an unanticipated problem during a study?

Continue the study as usual
Alter the study protocol without approval
Report the problem to authorities and assess risks (Correct answer)
Ignore the issue

Correct answer: Report the problem to authorities and assess risks

When an unanticipated problem arises during a study, it is crucial for investigators to promptly report it to the Institutional Review Board (IRB) or other relevant authorities. This ensures that the problem is thoroughly assessed for its impact on participant safety and the study's integrity, allowing for appropriate corrective actions to be taken.

Question 43: A participant in a randomized controlled trial experiences an unexpected drug interaction requiring emergency hospitalization. The investigator should document this as:

A minor safety finding to be reported at the next scheduled data review
A protocol deviation since hospitalization was not part of the protocol
A serious adverse event (SAE) requiring expedited reporting (Correct answer)
An adverse event (AE) only if the participant requests it

Correct answer: A serious adverse event (SAE) requiring expedited reporting

Any hospitalization or prolongation of hospitalization that is unexpected meets the definition of a serious adverse event requiring expedited reporting.

Question 44: RECIST 1.1 criteria for tumor response assessment classify a ≥30% decrease in the sum of diameters of target lesions as:

Partial Response (PR) (Correct answer)
Stable Disease (SD)
Progressive Disease (PD)
Complete Response (CR)

Correct answer: Partial Response (PR)

RECIST 1.1 defines Partial Response (PR) as at least a 30% decrease in the sum of diameters of target lesions compared to baseline.

Question 45: A Phase I dose-escalation study in oncology most commonly uses the 3+3 design to determine the:

Recommended Phase III dose
Pharmacokinetic half-life
Maximum tolerated dose (MTD) (Correct answer)
Minimum effective dose

Correct answer: Maximum tolerated dose (MTD)

The 3+3 design escalates doses in cohorts of three patients and defines the MTD based on dose-limiting toxicity occurrence.

Question 46: A site receives an investigational product that requires storage at room temperature (15°C–30°C). The site's storage room routinely reaches 32°C in summer. What should the investigator do?

Store the product as-is and document the temperature in the accountability log
Place the product in the refrigerator as a precaution
Notify the sponsor, identify an appropriate storage area meeting specifications, and do not dispense product until compliant storage is confirmed (Correct answer)
Dispense the product immediately before temperature-related degradation occurs

Correct answer: Notify the sponsor, identify an appropriate storage area meeting specifications, and do not dispense product until compliant storage is confirmed

Before dispensing, the site must ensure IP is stored per protocol specifications; exceeding the allowed temperature range requires sponsor notification and resolution of the storage issue before any product is used.

Question 47: What does the term 'intention-to-treat' (ITT) analysis mean?

All randomized participants are analyzed in the group they were assigned to, regardless of adherence (Correct answer)
Analysis is limited to participants who met all inclusion criteria
Only participants who completed the study are analyzed
Participants are analyzed based on the treatment they actually received

Correct answer: All randomized participants are analyzed in the group they were assigned to, regardless of adherence

ITT analysis preserves randomization integrity by including all participants in their assigned groups, even if they did not complete or adhere to the assigned treatment.

Question 48: A clinical trial participant becomes incapacitated mid-study and can no longer provide ongoing consent. The investigator should:

Continue study procedures as originally consented
Discontinue all study procedures immediately without LAR consultation
Consult the IRB before taking any action
Obtain consent from a legally authorized representative and reassess continued participation (Correct answer)

Correct answer: Obtain consent from a legally authorized representative and reassess continued participation

When a participant loses capacity, a legally authorized representative must be engaged to provide proxy consent before study procedures continue.

Question 49: Which ICH guideline provides the framework for clinical safety data management and expedited adverse drug reaction reporting?

ICH E8
ICH E10
ICH E2A (Correct answer)
ICH E6 (GCP)

Correct answer: ICH E2A

ICH E2A defines clinical safety data management, including definitions and standards for expedited reporting of serious adverse drug reactions during clinical development.

Question 50: What is the purpose of participant confidentiality in clinical trials?

To ensure privacy and protect sensitive information (Correct answer)
To improve recruitment
To speed up the trial
To avoid exposing data

Correct answer: To ensure privacy and protect sensitive information

Participant confidentiality in clinical trials is essential to protect individuals' privacy and maintain trust in the research process. It involves safeguarding personal and health information collected during a study, ensuring it is not disclosed to unauthorized parties. Upholding confidentiality is a fundamental ethical and legal requirement, preventing potential harm or discrimination to participants.

Question 51: Which document outlines the globally accepted ethical principles for conducting research involving human subjects that emerged from the Nuremberg trials?

Nuremberg Code (Correct answer)
Common Rule (45 CFR 46)
Declaration of Helsinki
Belmont Report

Correct answer: Nuremberg Code

The Nuremberg Code (1947) established foundational ethical principles for human experimentation, including voluntary consent, after Nazi war crimes.

Question 52: A new antibiotic study drug demonstrates a post-antibiotic effect (PAE). What does this mean for dosing strategy in the clinical trial?

The drug may be effective with less frequent dosing intervals (Correct answer)
The drug must be given more frequently to maintain efficacy
The drug's efficacy depends solely on peak concentration
PAE indicates the drug is bacteriostatic rather than bactericidal

Correct answer: The drug may be effective with less frequent dosing intervals

PAE refers to continued bacterial suppression after drug concentrations fall below MIC, allowing for extended dosing intervals without loss of efficacy.

Question 53: Patient-Reported Outcomes (PROs) in clinical trials must be collected in a standardized way to ensure data validity. Which practice is MOST important?

Translating PRO instruments informally for non-English speaking subjects
Having the study coordinator complete PRO forms on behalf of the subject to ensure accuracy
Allowing subjects to complete PRO instruments independently before clinical assessments and without coaching (Correct answer)
Collecting PRO data only at baseline and end of study

Correct answer: Allowing subjects to complete PRO instruments independently before clinical assessments and without coaching

PROs must be completed independently by subjects before clinical assessments to avoid bias; coaching or staff completion undermines the self-report validity that PROs are designed to capture.

Question 54: What is the investigator's responsibility when the IRB requests modifications to the study protocol before granting approval?

Implement the requested modifications and resubmit for IRB review before starting the study (Correct answer)
Begin the study under the original protocol and address modifications later
Submit the modification requests to the FDA for final determination
Proceed with enrollment while modifications are under review

Correct answer: Implement the requested modifications and resubmit for IRB review before starting the study

Investigators must not begin a study until the IRB has reviewed and approved the protocol, including any modifications the IRB requires.

Question 55: Who is primarily responsible for reporting SAEs to the clinical trial sponsor?

The IRB chairperson
The principal investigator or sub-investigator at the site (Correct answer)
The Data Safety Monitoring Board
The FDA district office

Correct answer: The principal investigator or sub-investigator at the site

The principal investigator is responsible for promptly reporting all SAEs to the sponsor, who then evaluates and submits required safety reports to the FDA.

Question 56: Which of the following best describes 'data lock' (database lock) in a clinical trial?

Finalizing and freezing the database after all queries are resolved so no further changes can be made before analysis (Correct answer)
Locking individual CRF pages as they are completed at each visit
Archiving the database at the end of the retention period
Encrypting the database to prevent unauthorized access during the trial

Correct answer: Finalizing and freezing the database after all queries are resolved so no further changes can be made before analysis

Database lock is the point at which all queries are resolved and the database is frozen, ensuring the analysis dataset cannot be altered.

Question 57: Which document should an investigator reference first when a study participant presents with a potential overdose of the investigational product?

The protocol appendix on discontinuation criteria
The Investigator's Brochure (IB) toxicity and overdose management section (Correct answer)
The IRB approval letter
The FDA 1572 form

Correct answer: The Investigator's Brochure (IB) toxicity and overdose management section

The Investigator's Brochure contains known toxicity data, overdose management guidance, and relevant safety information for the investigational product.

Question 58: Which form is used to report post-market safety problems with FDA-regulated products to the FDA?

IND Annual Report Form
FDA Form 1572
FDA MedWatch Form 3500 (Correct answer)
FDA Form 483

Correct answer: FDA MedWatch Form 3500

MedWatch Form 3500 (voluntary) or 3500A (mandatory for industry) is the FDA's safety reporting form for adverse events with regulated products.

Question 59: What is the primary reason for maintaining accurate and contemporaneous source records in a clinical trial?

To provide a verifiable audit trail that ensures data integrity and supports patient safety oversight (Correct answer)
To satisfy sponsor billing requirements
To minimize the number of monitoring visits required
To fulfill academic publication requirements

Correct answer: To provide a verifiable audit trail that ensures data integrity and supports patient safety oversight

Contemporaneous source records create an auditable trail that allows verification of safety data, supports regulatory review, and ensures accountability.

Question 60: A subject in a double-blind trial develops symptoms suggesting the study drug rather than placebo. The investigator considers unblinding. In what circumstance is emergency unblinding justified?

When knowledge of treatment assignment is essential for subject safety or medical management (Correct answer)
When the IRB requests interim efficacy data
When the subject requests to know their treatment assignment
When the investigator is curious about the subject's treatment assignment

Correct answer: When knowledge of treatment assignment is essential for subject safety or medical management

Emergency unblinding is justified only when knowing the treatment assignment is medically necessary for subject safety.

Question 61: Which element is NOT required in an investigator's SAE narrative report?

Temporal relationship between study drug and event
Treatment given and outcome of the event
Participant's financial status and insurance coverage (Correct answer)
Relevant medical history and concomitant medications

Correct answer: Participant's financial status and insurance coverage

SAE narratives require clinical details including timeline, medical history, concomitant medications, treatment, and outcome—financial or insurance details are irrelevant.

Question 62: What is a cohort study?

A study that tracks people over time (Correct answer)
A one-time observational study
A study with random treatment assignments
A laboratory-based experiment

Correct answer: A study that tracks people over time

A cohort study is an observational research design that tracks a group of individuals (a cohort) over an extended period to observe the development of specific outcomes or diseases. Researchers identify a group with a common characteristic or exposure and follow them forward in time. This longitudinal approach allows for the investigation of potential causes and risk factors for various health conditions.

Question 63: What should an investigator do if they believe the sponsor's monitoring visit findings are inaccurate?

Refuse to sign the monitoring report until all discrepancies are resolved
Sign the monitoring report under protest and file a formal grievance with the FDA
Discuss the discrepancy with the monitor and document their position in writing (Correct answer)
Accept the findings as the sponsor's monitor is the regulatory authority

Correct answer: Discuss the discrepancy with the monitor and document their position in writing

Investigators should resolve disagreements with monitors through professional dialogue and document their position in writing for the record.

Question 64: When a clinical trial is terminated early due to safety concerns, the investigator is required to:

Archive records immediately and close the site without participant notification
Continue follow-up visits only for participants who consent to the extended monitoring
Transfer participant records to the sponsor without informing participants
Notify all participants, ensure appropriate follow-up care, and submit a final report to the IRB (Correct answer)

Correct answer: Notify all participants, ensure appropriate follow-up care, and submit a final report to the IRB

Early termination requires notifying all participants, arranging appropriate medical follow-up, and submitting closure reports to the IRB and sponsor per regulatory requirements.

Question 65: A subject in a blinded study takes twice the prescribed dose for one week due to a misunderstanding. Under drug accountability principles, how should this be handled?

Ignore the event since the subject self-reported and no harm occurred
Adjust future dispensing quantities upward to compensate for the overuse
Withdraw the subject without documentation to protect their privacy
Document the protocol deviation, record the quantity consumed in the accountability log, assess for safety implications, and notify the sponsor and IRB as required (Correct answer)

Correct answer: Document the protocol deviation, record the quantity consumed in the accountability log, assess for safety implications, and notify the sponsor and IRB as required

Overdosing constitutes a protocol deviation that must be documented in both the accountability records and the subject's study file, with safety assessment and sponsor/IRB notification per protocol requirements.

Question 66: What is peer review in CPI Patient Assessment & Evaluation?

Reducing workloads
Determining promotions
Creating competition
Quality evaluation by qualified colleagues for improvement (Correct answer)

Correct answer: Quality evaluation by qualified colleagues for improvement

Peer review provides objective assessment by qualified professionals to identify improvements and ensure accountability.

Question 67: A subject misses a scheduled assessment window for a key efficacy endpoint. The study team obtains the assessment 5 days outside the protocol window. How should this be handled?

Continue as if no deviation occurred and record the visit as on-time
Discard the out-of-window data as it cannot be used
Document the deviation, collect the assessment, and report the protocol deviation per site procedures (Correct answer)
Withdraw the subject from the study immediately

Correct answer: Document the deviation, collect the assessment, and report the protocol deviation per site procedures

Out-of-window assessments should still be collected for subject safety, documented as a protocol deviation, and reported according to site and sponsor procedures.

Question 68: What are record retention policies in CPI practice?

Paper storage only
Rules defining how long records must be kept and when destroyed (Correct answer)
Keeping everything forever
Destroying records yearly

Correct answer: Rules defining how long records must be kept and when destroyed

Retention policies establish consistent guidelines based on legal requirements and business needs.

Question 69: Which document informs research subjects of their rights regarding the use and disclosure of their protected health information under HIPAA?

The protocol synopsis
The IRB approval letter
The HIPAA Authorization Form (Correct answer)
The Investigator's Brochure

Correct answer: The HIPAA Authorization Form

The HIPAA Authorization Form specifically describes how a subject's protected health information may be used or disclosed for research purposes, satisfying Privacy Rule requirements.

Question 70: During a clinical trial, which of the following would constitute a breach of aseptic technique when preparing an injectable investigational product?

Cleaning the vial stopper with 70% alcohol and allowing it to dry
Using a sterile needle to withdraw the product
Preparing the product outside a biological safety cabinet (Correct answer)
Labeling the syringe immediately after preparation

Correct answer: Preparing the product outside a biological safety cabinet

Injectable investigational products must be prepared in a sterile environment (e.g., biological safety cabinet or ISO 5 clean room) to prevent microbial contamination.

Question 71: Why is blinding important in clinical trials?

To speed up the study
To reduce bias (Correct answer)
To increase recruitment
To increase treatment frequency

Correct answer: To reduce bias

Blinding is crucial in clinical trials to reduce bias by concealing treatment assignments from participants, researchers, or both. If participants know they are receiving an active treatment, their expectations might influence their reported symptoms (placebo effect). Similarly, if researchers know the assignments, it could unconsciously affect how they assess outcomes. Blinding ensures objectivity and strengthens the validity of the study results.

Question 72: A participant in an oncology trial develops grade 3 thrombocytopenia (platelets 25,000/µL). Per ICH E6 GCP guidelines, what is the investigator's primary obligation regarding this event?

Discontinue all study medications immediately without assessment
Continue the study drug with dose reduction and observe
Report only to the IRB and not the sponsor
Assess causality, treat the participant, and report as a serious adverse event to the sponsor (Correct answer)

Correct answer: Assess causality, treat the participant, and report as a serious adverse event to the sponsor

Grade 3 thrombocytopenia is serious; the investigator must ensure participant safety, assess causality, and report the SAE to the sponsor within required timeframes per ICH E6.

Question 73: A Data Safety Monitoring Board (DSMB) recommends immediate trial suspension due to a safety signal. The investigator's responsibility is to:

Await IRB confirmation before stopping any study activities
Continue only with participants already enrolled but stop new enrollment
Continue enrolling until the sponsor issues an official stop order
Immediately halt enrollment and notify all participants currently on study drug (Correct answer)

Correct answer: Immediately halt enrollment and notify all participants currently on study drug

Upon a DSMB safety-based suspension recommendation communicated through the sponsor, investigators must immediately halt enrollment and take steps to protect current participants.

Question 74: What is evidence-based practice in CPI Patient Assessment & Evaluation?

Integrating research evidence with expertise and client needs (Correct answer)
Using newest unproven methods
Following intuition only
Doing whatever clients request

Correct answer: Integrating research evidence with expertise and client needs

Evidence-based practice combines research, expertise, and client preferences for optimal outcomes.

Question 75: Which of the following blood-borne pathogens has the highest transmission risk after a needlestick injury from an infected source?

Hepatitis C virus (HCV)
HIV
Hepatitis B virus (HBV) (Correct answer)
Cytomegalovirus (CMV)

Correct answer: Hepatitis B virus (HBV)

HBV has the highest transmission risk per needlestick (~30%), compared to ~3% for HCV and ~0.3% for HIV.

Question 76: A sponsor issues an urgent safety communication notifying investigators of a new contraindication discovered during a trial. The investigator's FIRST action should be:

Await FDA guidance before acting on the sponsor's communication
Discuss the communication at the next investigator meeting
Review currently enrolled participants for the contraindication and take protective action immediately (Correct answer)
Notify the IRB and wait for approval before reviewing participant records

Correct answer: Review currently enrolled participants for the contraindication and take protective action immediately

Upon receipt of urgent safety communications, investigators must immediately assess enrolled participants for risk and take protective action without delay.

Question 77: In a protocol, the 'estimand' framework (ICH E9(R1)) defines which of the following?

The sequence of hypothesis testing for secondary endpoints
The statistical software to be used for primary analysis
The precise treatment effect to be estimated, including the target population, endpoint, and intercurrent event handling (Correct answer)
The minimum detectable difference required for sample size calculation

Correct answer: The precise treatment effect to be estimated, including the target population, endpoint, and intercurrent event handling

The estimand framework defines exactly what treatment effect is being estimated, including the population, endpoint, and how intercurrent events (like discontinuation) are handled.

Question 78: What does residual risk mean in CPI practice?

Initial risk before assessment
Risk affecting waste materials
Budget overrun risk
Risk remaining after all controls are implemented (Correct answer)

Correct answer: Risk remaining after all controls are implemented

Residual risk is the level remaining after practical controls are applied. Some is usually accepted as eliminating all risk is rarely feasible.

Question 79: Which of the following best describes the researcher's obligation under the 'respect for persons' principle when enrolling prisoners?

Enrollment requires additional safeguards because incarceration may compromise voluntariness (Correct answer)
Prisoner enrollment requires only warden approval, not IRB special review
Prisoners may never be enrolled in clinical trials under any circumstances
Prisoners need no special protections since they are adults

Correct answer: Enrollment requires additional safeguards because incarceration may compromise voluntariness

Prisoners are a protected class because coercive institutional settings threaten voluntariness, requiring enhanced IRB scrutiny per 45 CFR 46 Subpart C.

Question 80: What is a randomized controlled trial (RCT)?

A clinical study without controls
A study with random selection of participants
A study with random assignment of interventions (Correct answer)
A trial with no treatment

Correct answer: A study with random assignment of interventions

A Randomized Controlled Trial (RCT) is a type of clinical study where participants are randomly assigned to different intervention groups, typically receiving either the experimental treatment or a control (e.g., placebo or standard care). This random assignment minimizes bias and ensures that the groups are comparable at the start of the study. RCTs are considered the gold standard for evaluating the efficacy and safety of new interventions.

Question 81: A study participant is hospitalized for an SAE. The investigator's source document responsibilities include:

Documents only if the event is deemed possibly related to study drug
A brief notation in the research file that hospitalization occurred
Hospital records, lab results, and a narrative linking the event to study participation (Correct answer)
Only the sponsor's case report form (CRF) entries

Correct answer: Hospital records, lab results, and a narrative linking the event to study participation

Complete source documentation for SAEs includes all medical records, lab data, and a narrative account regardless of causality assessment.

Question 82: A participant enrolled in a placebo-controlled trial develops symptoms strongly suggesting they are in the control arm. They request unblinding to pursue open-label treatment. What should the investigator do?

Deny the request to protect trial integrity under all circumstances
Transfer the participant to another study without unblinding
Follow the protocol's unblinding procedures, which typically require a clinical safety justification and sponsor notification (Correct answer)
Unblind the participant immediately upon request

Correct answer: Follow the protocol's unblinding procedures, which typically require a clinical safety justification and sponsor notification

Emergency unblinding should follow predefined protocol procedures requiring clinical justification, protecting both safety and data integrity.

Question 83: Under 21 CFR 50.25, which of the following is classified as an ADDITIONAL element of informed consent (rather than a basic required element)?

Disclosure that a particular treatment or procedure may involve currently unforeseeable risks to a participant or embryo if pregnant (Correct answer)
A description of foreseeable risks or discomforts to the participant
A statement that records may be inspected by FDA
An explanation of the purpose of the research

Correct answer: Disclosure that a particular treatment or procedure may involve currently unforeseeable risks to a participant or embryo if pregnant

The disclosure of unforeseeable risks to participants or embryos is listed under 21 CFR 50.25(b) as an additional element, not a basic required one.

Question 84: In a trial of a topical dermatological agent, systemic absorption is measured to assess safety. The bioavailability is 3%. A participant applies the cream to 40% of their body surface (BSA) due to widespread psoriasis instead of the protocol-specified 10% BSA. What is the safety concern?

Decreased local drug concentration due to larger application area
Disproportionate systemic exposure due to increased absorption surface area (Correct answer)
Reduced efficacy due to dilution of the drug across larger skin area
No systemic concern as topical drugs do not achieve systemic levels

Correct answer: Disproportionate systemic exposure due to increased absorption surface area

Systemic absorption of topical drugs correlates with surface area of application; applying to 4× the protocol BSA can lead to significantly higher systemic exposure and potential systemic toxicity.

Question 85: Under ICH E6(R2), which of the following is the investigator's responsibility regarding delegation of trial-related duties?

Delegation requires FDA pre-approval for each staff member
Investigators may delegate any task to any staff member without documentation
Only co-investigators may receive delegated duties; other staff are excluded
Investigators must maintain a delegation log listing qualified personnel and their assigned responsibilities (Correct answer)

Correct answer: Investigators must maintain a delegation log listing qualified personnel and their assigned responsibilities

ICH E6(R2) requires investigators to maintain a delegation log documenting which qualified staff members have been assigned specific trial tasks.

Question 86: Under GCP guidelines, which document formally authorizes staff to manage emergencies at a clinical trial site?

The IRB approval certificate
The site's delegation of authority log signed by the PI (Correct answer)
The FDA Form 1572
The protocol signature page

Correct answer: The site's delegation of authority log signed by the PI

The delegation of authority log specifies which staff members are authorized to perform specific study tasks, including emergency medical response procedures.

Question 87: Which ethical principle from the Belmont Report requires that the potential benefits of research justify the risks to participants?

Autonomy
Beneficence (Correct answer)
Justice
Respect for Persons

Correct answer: Beneficence

Beneficence requires researchers to maximize possible benefits and minimize possible harms, ensuring benefits justify risks.

Question 88: At what reading level should informed consent documents ideally be written, per FDA and OHRP guidance?

Graduate level for complex medical studies
8th grade or below (Correct answer)
College level (12th grade)
10th grade

Correct answer: 8th grade or below

FDA and OHRP recommend consent documents be written at an 8th-grade reading level or below to ensure comprehension across diverse subject populations.

Question 89: The Karnofsky Performance Status scale scores subjects from 0 to 100. A subject who requires occasional assistance but can care for most personal needs has a Karnofsky score of approximately:

50
100
70 (Correct answer)
80

Correct answer: 70

A Karnofsky score of 70 describes a subject who cares for themselves but is unable to carry on normal activity or active work, requiring occasional assistance.

Question 90: What is the principle of respect for persons in ethical research?

Ensuring non-disclosure
Ensuring payment
Respect for their opinions
Voluntary participation and informed consent (Correct answer)

Correct answer: Voluntary participation and informed consent

The principle of respect for persons in ethical research emphasizes the autonomy of individuals and the protection of those with diminished autonomy. This means that participants must voluntarily agree to participate in research, free from coercion or undue influence. Informed consent, where individuals are fully apprised of the study's nature, risks, and benefits before agreeing, is the cornerstone of this principle.

Question 91: Why is it important to maintain accurate research records?

To reduce costs
To meet publication requirements
To monitor progress
To ensure data accuracy and transparency (Correct answer)

Correct answer: To ensure data accuracy and transparency

Maintaining accurate and complete research records is essential for the credibility and reproducibility of clinical research. Meticulous record-keeping ensures that all data can be verified, supports the transparency of the research process, and allows for proper auditing and regulatory oversight.

Question 92: A study drug is administered as a prodrug that requires hepatic conversion to its active metabolite. A participant with Child-Pugh Class C cirrhosis enrolls. What is the primary concern?

Increased renal clearance of the active metabolite
Impaired prodrug activation leading to reduced efficacy (Correct answer)
Enhanced prodrug activation causing toxicity
No effect as prodrugs bypass hepatic metabolism

Correct answer: Impaired prodrug activation leading to reduced efficacy

Severe hepatic impairment reduces the enzymatic capacity to convert prodrugs to active forms, potentially rendering the drug ineffective in participants with Child-Pugh C cirrhosis.

Question 93: What action is required when a shipment of investigational product arrives at the clinical site?

Inspect shipment, verify contents against shipping manifest, and document receipt in accountability log (Correct answer)
Repackage in study-blind containers before logging receipt
Immediately distribute to subjects to avoid storage fees
Return unopened to sponsor until IRB approval is confirmed

Correct answer: Inspect shipment, verify contents against shipping manifest, and document receipt in accountability log

Upon receipt, site staff must inspect the shipment for damage, verify contents against the shipping manifest, check storage conditions during transit, and document the receipt in the drug accountability log.

Question 94: Which federal office is responsible for overseeing human research protections, including informed consent compliance?

Office for Human Research Protections (OHRP) (Correct answer)
NIH Office of Research Integrity (ORI)
CMS Center for Clinical Standards
FDA Center for Drug Evaluation and Research (CDER)

Correct answer: Office for Human Research Protections (OHRP)

OHRP oversees compliance with the Common Rule (45 CFR Part 46) and is the primary federal office responsible for protecting human research subjects.

Question 95: A female subject of childbearing potential is being screened for a clinical trial involving a teratogenic investigational drug. Which pregnancy test result is required before enrollment?

A negative serum or urine pregnancy test within the timeframe specified in the protocol (Correct answer)
A verbal confirmation from the subject that she is not pregnant
A negative test result on file from her primary care physician
A negative urine pregnancy test performed any time in the prior month

Correct answer: A negative serum or urine pregnancy test within the timeframe specified in the protocol

Protocols involving teratogenic agents require a documented negative pregnancy test within the protocol-specified window (typically 24-72 hours before enrollment) to confirm eligibility.

Question 96: Within what timeframe must an investigator report a fatal or life-threatening unexpected SAE to the FDA under 21 CFR 312.32?

Within 7 calendar days (Correct answer)
Within 48 hours
Within 30 calendar days
Within 15 calendar days

Correct answer: Within 7 calendar days

Fatal or life-threatening unexpected serious adverse drug reactions must be reported to the FDA as an IND safety report within 7 calendar days of the investigator becoming aware.

Question 97: A CPI learns that a colleague has fabricated patient data in a clinical trial. What is the most appropriate immediate action?

Report the misconduct to the IRB, sponsor, and relevant institutional authorities (Correct answer)
Confront the colleague privately and give them time to self-correct
Ignore it if the overall study data appear valid
Withdraw from the trial without informing anyone to avoid conflict

Correct answer: Report the misconduct to the IRB, sponsor, and relevant institutional authorities

Research misconduct must be reported to protect participants and the integrity of science; self-correction by the offending party is insufficient.

Question 98: Under 21 CFR Part 312, what is the maximum timeframe within which an investigator must report an unexpected serious adverse event to the IRB?

Within 10 working days
Within 30 days
Within 7 calendar days (Correct answer)
Within 24 hours

Correct answer: Within 7 calendar days

Unexpected serious adverse events must be reported to the IRB within 7 calendar days under 21 CFR Part 312.

Question 99: What is a 'short form' written consent document?

A document stating that required elements were presented orally and the subject agrees (Correct answer)
An abbreviated consent used for telephone screening
A consent form approved for use without IRB review
A one-page summary replacing the full consent form for low-risk studies

Correct answer: A document stating that required elements were presented orally and the subject agrees

A short form consent document states that the elements of informed consent were orally presented to the subject or LAR, and requires a witness signature and written summary of what was presented.

Question 100: What is the importance of informed consent in clinical research?

To increase recruitment
To speed up data collection
To reduce research costs
To ensure participants understand the study and risks involved (Correct answer)

Correct answer: To ensure participants understand the study and risks involved

Informed consent is a fundamental ethical principle in clinical research, ensuring that potential participants voluntarily agree to participate after fully understanding the study's purpose, procedures, potential risks, and benefits. This process empowers individuals to make autonomous decisions about their involvement and protects their rights.

Question 101: What is the purpose of a placebo in clinical trials?

To improve the outcome
To monitor side effects
To act as a control group (Correct answer)
To increase patient adherence

Correct answer: To act as a control group

The purpose of a placebo in clinical trials is to serve as a control group, allowing researchers to isolate the true effects of the active treatment. A placebo is an inactive substance or treatment that looks identical to the active intervention. By comparing outcomes between the active treatment group and the placebo group, researchers can differentiate between the actual pharmacological effects and effects due to patient expectation or natural disease progression.

Question 102: Under FDA regulations, how long must a clinical investigator retain signed informed consent documents?

Indefinitely
5 years after study completion
2 years after the study's marketing application or IND discontinuation (Correct answer)
1 year after study completion

Correct answer: 2 years after the study's marketing application or IND discontinuation

Per 21 CFR 312.62, investigators must retain consent documents for at least 2 years following the date of marketing application approval or IND discontinuation.

Question 103: What is a records management audit in CPI?

Counting filing cabinets
Computer usage review
Reviewing practices to ensure compliance with policies (Correct answer)
Supplies inventory

Correct answer: Reviewing practices to ensure compliance with policies

This audit examines how records are created, stored, accessed, retained, and destroyed for compliance.

Question 104: When a source document error is discovered in a clinical trial, the correct procedure is to:

Cross out the error with a single line, initial, date, and note the reason (Correct answer)
Use correction fluid to cover the mistake before writing the correction
Delete the original entry and rewrite it
Leave the error and add a sticky note explaining it

Correct answer: Cross out the error with a single line, initial, date, and note the reason

ICH GCP requires that corrections preserve the original entry by crossing it out with a single line, then initialing, dating, and providing a reason for the correction.

Question 105: A participant in a blinded clinical trial requires emergency surgery and the surgeon needs to know the study drug. What is the correct action?

Use the emergency unblinding procedure to reveal the participant's treatment assignment (Correct answer)
Treat the participant as if on placebo until the blind can be broken formally
Discontinue the participant without unblinding
Contact the sponsor's medical monitor first

Correct answer: Use the emergency unblinding procedure to reveal the participant's treatment assignment

Emergency unblinding procedures exist to protect participant safety; the investigator should use the defined emergency unblinding process immediately.

Question 106: What is the purpose of data collection in clinical research?

To recruit participants
To gather and analyze information for evaluating treatments (Correct answer)
To monitor side effects
To monitor patient progress

Correct answer: To gather and analyze information for evaluating treatments

Data collection is the systematic process of acquiring relevant information in clinical research to address the study's objectives. This data is then rigorously analyzed to evaluate the safety and efficacy of new treatments or interventions, ultimately informing medical practice and patient care.

Question 107: A clinical trial involves a vulnerable population (cognitively impaired adults). Which additional patient safety safeguard is MOST important?

Excluding these participants from all safety reporting
Requiring a legally authorized representative to provide consent and monitoring for signs of undue influence (Correct answer)
Allowing verbal consent without written documentation
Increasing the financial compensation to ensure participation

Correct answer: Requiring a legally authorized representative to provide consent and monitoring for signs of undue influence

Vulnerable populations require heightened protections, including surrogate consent from a legally authorized representative and vigilance against coercion.

Question 108: Under 21 CFR Part 312, what is the investigator's obligation when they permanently discontinue or temporarily suspend a clinical investigation?

Immediately notify the IRB and the sponsor of the discontinuation (Correct answer)
Destroy all investigational product and study records
Notify the FDA within 30 days via Form FDA 1572
Complete all subject follow-up visits before notifying any party

Correct answer: Immediately notify the IRB and the sponsor of the discontinuation

The investigator must promptly notify both the IRB and sponsor when discontinuing or suspending an investigation.

Question 109: Which of the following represents an investigator's financial conflict of interest that MUST be disclosed?

Being reimbursed for travel to an investigator meeting
Receiving standard speaker fees from a medical society unrelated to the trial drug
Receiving grant funding from NIH for an unrelated study
Holding equity interest in the company sponsoring the trial (Correct answer)

Correct answer: Holding equity interest in the company sponsoring the trial

Equity interest in the sponsoring company creates a significant financial conflict of interest that must be disclosed to the FDA and IRB per 21 CFR Part 54.

Question 110: Post-exposure prophylaxis (PEP) for HIV after a needlestick should ideally be initiated within:

48 hours
72 hours (Correct answer)
1 week
24 hours

Correct answer: 72 hours

HIV PEP should be started as soon as possible and ideally within 2 hours, but remains effective if initiated within 72 hours of exposure.

Question 111: A clinical trial site receives a shipment of investigational vaccines requiring storage at 2–8°C. Upon arrival, the refrigerator temperature log shows an excursion to 12°C overnight. The PI should FIRST:

Quarantine the vaccines and contact the sponsor (Correct answer)
Discard the vaccines immediately
Report the excursion to the FDA
Administer the vaccines as the excursion was brief

Correct answer: Quarantine the vaccines and contact the sponsor

Vaccines affected by a temperature excursion must be quarantined and the sponsor contacted to assess viability before any use or disposal.

Question 112: Which of the following is the BEST example of a validated patient-reported outcome (PRO) instrument?

Investigator global assessment scored at clinic visits
Nurse-completed symptom checklist based on patient interview
A disease-specific quality-of-life questionnaire developed and validated per FDA PRO guidance (Correct answer)
A single question created by the investigator for convenience

Correct answer: A disease-specific quality-of-life questionnaire developed and validated per FDA PRO guidance

A PRO instrument must be developed and validated according to FDA PRO guidance to demonstrate it measures what it intends to measure reliably.

Question 113: A Phase II protocol uses a 'Simon two-stage design.' What is the purpose of the first stage in this design?

To complete full enrollment before any efficacy analysis
To allow early termination for futility if insufficient responses are observed in the initial cohort (Correct answer)
To randomize subjects to multiple treatment arms before selecting the best arm
To assess pharmacokinetics before initiating the efficacy phase

Correct answer: To allow early termination for futility if insufficient responses are observed in the initial cohort

The Simon two-stage design allows early stopping for futility after Stage 1 if the response rate does not meet a pre-specified threshold, conserving resources.

Question 114: A sub-investigator at a clinical trial site wants to enroll a relative as a research subject. What is the BEST course of action?

Have the relative sign a waiver of conflict and proceed normally
Allow enrollment only if the relative provides written permission to the IRB
Allow enrollment since the sub-investigator can objectively evaluate the relative
Decline enrollment or ensure an independent evaluator obtains consent to avoid undue influence (Correct answer)

Correct answer: Decline enrollment or ensure an independent evaluator obtains consent to avoid undue influence

Enrolling relatives creates a coercive situation; an independent party should obtain consent or the subject should not be enrolled to protect voluntary participation.

Question 115: What is quantitative data in clinical research?

Subjective reports from participants
Non-numerical information
Numerical measurements used for statistical analysis (Correct answer)
Patient questionnaires

Correct answer: Numerical measurements used for statistical analysis

Quantitative data in clinical research involves measurable information that can be expressed numerically, such as dosages, patient ages, blood pressure readings, or symptom scores. This type of data is crucial for statistical analysis, allowing researchers to identify patterns, test hypotheses, and draw objective conclusions about treatment effects.

Question 116: What is the importance of continuing education for CPI professionals in Patient Assessment & Evaluation?

Justifying higher fees
Only for new professionals
Maintaining current knowledge and adapting to industry changes (Correct answer)
Filling time between engagements

Correct answer: Maintaining current knowledge and adapting to industry changes

Continuing education keeps professionals current with developments and best practices while meeting certification requirements.

Question 117: A participant with mild cognitive impairment wishes to enroll in a clinical trial. Which approach best satisfies ethical requirements?

Enroll the participant using only surrogate consent without assessing personal capacity
Assess decision-making capacity individually and involve a legally authorized representative if needed (Correct answer)
Exclude the participant automatically due to impaired cognition
Obtain verbal consent only, as written consent may be confusing

Correct answer: Assess decision-making capacity individually and involve a legally authorized representative if needed

Capacity must be assessed individually; participants who retain sufficient capacity should consent themselves, with a LAR involved if capacity is insufficient.

Question 118: How does professional liability insurance protect CPI practitioners?

Paying health premiums
Protecting against equipment theft
Covering disaster damage
Covering financial losses from claims of negligence or errors (Correct answer)

Correct answer: Covering financial losses from claims of negligence or errors

This insurance covers financial consequences of claims alleging negligence or mistakes in professional services.

Question 119: What is the main limitation of an open-label extension (OLE) study?

It cannot collect long-term safety data
It requires a new IND submission
Results are confounded because participants and investigators know the treatment (Correct answer)
Blinding is strengthened compared to the parent study

Correct answer: Results are confounded because participants and investigators know the treatment

In an OLE, unblinding introduces performance and detection bias, making it difficult to attribute outcomes solely to the drug.

Question 120: What is peer review in CPI Pharmacology & Medication Management?

Creating competition
Determining promotions
Quality evaluation by qualified colleagues for improvement (Correct answer)
Reducing workloads

Correct answer: Quality evaluation by qualified colleagues for improvement

Peer review provides objective assessment by qualified professionals to identify improvements and ensure accountability.

Question 121: Which of the following scenarios represents a serious breach of investigational product accountability that must be reported to the sponsor immediately?

A one-day delay in completing a drug return due to a site holiday
A subject returns 1 more tablet than expected due to a missed dose
A minor typographical error on a dispensing log corrected with a single strikethrough and initials
Investigational product is discovered missing from site inventory with no documentation explaining the loss (Correct answer)

Correct answer: Investigational product is discovered missing from site inventory with no documentation explaining the loss

Unexplained missing investigational product represents a potential diversion, safety hazard, or fraud that requires immediate sponsor notification and investigation to protect trial integrity and subject safety.

Question 122: What is a risk matrix used for in CPI practice?

Evaluating risks by plotting likelihood against impact severity (Correct answer)
Mapping facility layouts
Creating task schedules
Tracking attendance

Correct answer: Evaluating risks by plotting likelihood against impact severity

A risk matrix plots probability against consequences to prioritize which risks need immediate attention.

Question 123: A researcher notices that trial staff are not consistently performing hand hygiene between participant contacts. The MOST effective immediate intervention is:

Report the breach to the IRB immediately
Suspend the trial pending retraining
Install alcohol-based hand rub dispensers at point-of-care (Correct answer)
Send a memo reminding staff of policy

Correct answer: Install alcohol-based hand rub dispensers at point-of-care

Point-of-care placement of alcohol-based hand rub dispensers is the most effective environmental intervention to improve hand hygiene compliance.

Question 124: A randomized controlled trial uses a PROBE design. What does PROBE stand for?

Placebo-controlled Randomized Observational Blinded Evaluation
Prospective Randomized Outcome-Based Evaluation
Prospective Randomized Open Blinded End-point (Correct answer)
Parallel Randomized Open-label Blinded Efficacy

Correct answer: Prospective Randomized Open Blinded End-point

PROBE (Prospective Randomized Open Blinded End-point) uses open-label treatment assignment but blinded endpoint assessment to reduce bias.

Question 125: An emergency protocol amendment is submitted to the IRB to allow a new rescue medication. Under which condition may the investigator implement the amendment before IRB approval?

When immediate use is necessary to eliminate apparent immediate hazard to participants (Correct answer)
When the amendment involves only minor procedural changes
Never; all amendments require prior IRB approval
When the sponsor provides written authorization

Correct answer: When immediate use is necessary to eliminate apparent immediate hazard to participants

Under 21 CFR 56.108(a)(4), investigators may implement unapproved changes when necessary to eliminate an apparent immediate hazard, followed by prompt IRB notification.

Certified Principal Investigator (CPI®)

The CPI® certification validates the expertise of physicians and advanced practice clinicians serving as principal investigators in clinical trials, covering GCP compliance, ethical conduct, site management, and data integrity across all phases of clinical research.

Questions

40 min

Time Limit

70%

To Pass

Checking for saved progress...

Exam Rules

You can skip questions and return to them later
Flag questions for review before submitting
No feedback shown until you submit the entire exam
Unanswered questions count as wrong — answer everything
10 pretest questions are mixed in and don't affect your score
Timer auto-submits when time runs out
Your progress is auto-saved every 30 seconds